GLP-1(7-36) | CAS:119637-73-9

We serve GLP-1(7-36) CAS:119637-73-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
GLP-1(7-36)

Chemical Name:GLP-1(7-36)
CAS.NO:119637-73-9
Synonyms:GLP-1(7-36)
glucagon-like peptide I (7-36)amide
Glucagon-like peptide 1 (7-36)amide
GLP-1(7-36), IRP peptide
 
Physical and Chemical Properties:
Molecular Formula C151H229N41O46
Molecular Weight 3354.73
Specification:
Appearance:White to off-white powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Potent stimulator of insulin released in perfused mammalian pancreas.



Contact us for information like GLP-1(7-36) chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,GLP-1(7-36), IRP peptide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,GLP-1(7-36) Use and application,GLP-1(7-36) technical grade,usp/ep/jp grade.


Related News: Ten domestic API leading enterprises of CSPC, Puluo Pharmaceutical, Huahai Pharmaceutical, Chuang Nuo Pharmaceutical, Federal Pharmaceuticals, Zhejiang Pharmaceutical, Yifan Pharmaceutical, Jiangxi Tianxin, Zhejiang Chemical Industry, and Xinhua Pharmaceutical rank among China’s API exporters The top ten in the list.chlorotrimethylsilane manufacturer Ten domestic API leading enterprises of CSPC, Puluo Pharmaceutical, Huahai Pharmaceutical, Chuang Nuo Pharmaceutical, Federal Pharmaceuticals, Zhejiang Pharmaceutical, Yifan Pharmaceutical, Jiangxi Tianxin, Zhejiang Chemical Industry, and Xinhua Pharmaceutical rank among China’s API exporters The top ten in the list.N-(4-nitrophenyl)-3-oxobutanamide supplier Apple is temporarily closing all of its stores in China because of the coronavirus outbreak.2,6-Dichloro-4-(trifluoromethyl)phenylhydrazine vendor Apple is temporarily closing all of its stores in China because of the coronavirus outbreak.Under the terms of the agreement, ICIG will purchase substantially all of the pharmaceutical intermediates business, excluding the drug delivery technologies portion of the business.